Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution
Phase 1/2UNKNOWN 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endophthalmitis Postoperative
Conditions
Endophthalmitis Postoperative
Trial Timeline
Sep 23, 2019 → May 1, 2022
NCT ID
NCT04212429About Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution is a phase 1/2 stage product being developed by Santen Pharmaceutical for Endophthalmitis Postoperative. The current trial status is unknown. This product is registered under clinical trial identifier NCT04212429. Target conditions include Endophthalmitis Postoperative.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04212429 | Phase 1/2 | UNKNOWN |
Competing Products
2 competing products in Endophthalmitis Postoperative
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin Ophthalmic + Cefuroxime | Santen Pharmaceutical | Phase 1/2 | 41 |
| Levofloxacin Ophthalmic Solution + Moxifloxacin Ophthalmic Solution | Santen Pharmaceutical | Phase 1/2 | 41 |
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77